A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma.

Trial Profile

A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs BL 8040 (Primary)
  • Indications Multiple myeloma; Stem cell mobilisation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biokine Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Apr 2016 Results published as per BioLineRx Ltd media release.
    • 03 Feb 2015 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top